OnKure Therapeutics, Inc.

NASDAQ: OKUR · Healthcare · Biotechnology

PublicHQ Boulder, CO · BoulderCIK 0001637715Reports USD

#1161 of 1,418 Healthcare companies by revenue

EA Score

46D

FH 49DQ 41GM —SS 46

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, filing timeliness · ↓ disclosure history, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$59.5M

Employees

as of 2026-08-19

Market cap

$170.5M

as of 2026-08-19

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02024

Net income-$59.5M-$59.5M2025

Operating income-$63.0M-$63.0M2025

Total assets$62.1M$62.1M2025

Liabilities$5.9M$5.9M2025

Equity$56.2M$56.2M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is OnKure Therapeutics, Inc.’s revenue?

OnKure Therapeutics, Inc. booked $0 in FY2024 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Corbus Pharmaceuticals Holdings, Inc.46D Immuneering Corporation43D Nkarta, Inc.47D TuHURA Biosciences, Inc.36D Spruce Biosciences, Inc.40D Aardvark Therapeutics, Inc. Common Stock40D

Neighbors

Boulder →

Edgewise Therapeutics, Inc.——Enliven Therapeutics, Inc.——Infleqtion Inc——Solid Power, Inc.$17.9M38D Gores Holdings XI, Inc.——Gloo Holdings, Inc.$94.7M31D

Key facts

CEONicholas A. Saccomano

SectorHealthcare

IndustryBiotechnology

HeadquartersBoulder, CO

ExchangeNASDAQ: OKUR

Employees45

IPO date2021-04-08

Latest filings

8-K2026-08-13 8-K2026-08-04 10-Q2026-08-04 8-K2026-06-04 10-Q2026-05-05 8-K2026-05-05 DEF 14A2026-04-21 8-K2026-03-30

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.